The efficacy and safety of liraglutide, a long-acting GLP-1 analogue, was evaluated in patients with NASH, providing evidence that liraglutide was safe, well tolerated and mediated the histological resolution of NASH [44]. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.